Medicine

A two-part upgrade is planned for HIPA from 2025 to 2028. Preparations are already under way.

Newly established Focal Biosciences will focus on bringing together leading experts and scientific discoveries to harness cellular reprogramming in the fight against common age-related diseases.

Improved method thanks to a molecular trick

From research to production – the new pharmaceutical lab at PSI supplies neighbouring hospitals with novel cancer drugs.

Employing high-resolution X-rays to diagnose breast cancer – PSI researchers nominated for the European Inventor Award.

PSI is involved in the development of a breath test that can be used to diagnose asthma. Imad El Haddad explains why such a test could be extremely useful – especially for children.

The test identifies different virus variants and improves disease prognosis.

This gallery presents five people who have been treated at the PSI's Center for Proton Therapy.

Kantonsspital Baden and the Paul Scherrer Institute PSI have signed a cooperation agreement.

Combining two chemotherapeutic drugs inhibits tumour growth.

In partnership with Roche, PSI scientists are developing new, potentially more efficient catalysts for manufacturing active substances for drug therapies.

25 November 1996: a world first for PSI’s Center for Proton Therapy in treating a cancer patient using the spot-scanning technique.

On 9 November 2021 a lung cancer patient was given proton therapy at the Paul Scherrer Institute PSI for the first time in Switzerland.

PSI researchers identify potential active agent against several unicellular parasites – including the pathogens that cause malaria and toxoplasmosis.

The University Hospital of Zurich uses proteins made at PSI for Europe’s first large-scale serology study on coronavirus prevalence in Switzerland.

Crystal structure analysis, computer models, cell cultures – to pursue research on Sars-CoV-2, PSI is exploring many avenues. An overview.

A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases.

Researchers at Goethe University Frankfurt, in cooperation with the PSI have probably discovered another, previously unknown mechanism of action of the antiviral remdesivir.

Imaging and sequencing techniques combined with machine learning offer researchers countless opportunities to look inside cells with greater precision than ever before. G.V. Shivashankar, lab head at PSI, describes how such information can be used to find answers to pressing questions.